1Signaling at the orexin-1 receptor (Ox1R) is important for motivation for various drugs of abuse. 2 Recently, our laboratory showed that systemic blockade of Ox1Rs decreased motivation for the 3 potent and short-acting opioid remifentanil, as well as remifentanil consumption at null cost 4 (Porter-Stransky et al., 2017). However, the central site(s) through which orexin acts to regulate 5 opioid-seeking behaviors are not known. We investigated ventral pallidum (VP) as a potential 6 site of orexin action, as VP is a known mediator of opioid reward and is densely innervated by 7 orexin-immunoreactive fibers. We used a within-session behavioral economics (BE) paradigm in 8 which remifentanil price (responses/µg iv remifentanil) was sequentially increased throughout 9 the session. Rats were implanted with bilateral cannulae into caudal VP (cVP), through which 10 microinjections of SB334867 (SB), an Ox1R antagonist, were given prior to BE and 11 reinstatement testing. Contrary to systemic SB treatment, intra-cVP SB preferentially reduced 12 motivation (increased demand elasticity and reinstatement) for reminfentanil, without affecting 13 remifentanil consumption at null cost. These effects were specific to cVP, as control 14 microinjections of SB immediately dorsal to cVP did not affect remifentanil-seeking. Baseline 15 demand for remifentanil predicted cued reinstatement of remifentanil seeking and the efficacy 16 with which intra-cVP SB administration reduced motivation for remifentanil. These findings 17 indicate a specific role for cVP Ox1R signaling in mediating the motivational properties of the 18 opioid remifentanil, distinct from its consumption at null cost. Our findings also highlight the BE 19 paradigm as an effective biomarker for predicting opioid addiction behaviors and treatment 20 efficacy. 21 22 Introduction: 33 In recent years, abuse of prescription opioids has risen rapidly and has become a major health 34 issue (Compton and Volkow, 2006; Lewis et al., 2017; Volkow and Collins, 2017; Dobbs and 35 Fogger, 2018). Thus, it is urgent to understand the neurobiological and behavioral mechanisms 36 underlying opioid addiction to facilitate development of new treatments for this disorder. The 37 hypothalamic orexin (hypocretin) system is a key modulator of drug seeking behaviors across a 38 variety of drugs of abuse, including opioids (Harris et al., 2005; Mahler et al., 2014a; Baimel et 39 al., 2015; James et al., 2017). Orexin-containing neurons are located in hypothalamus and project 40 widely throughout the brain, targeting two G-protein-coupled receptors (orexin receptors 1 and 41 2; Ox1R and Ox2R, respectively). In particular, signaling at Ox1R has been shown to mediate 42 motivation and addiction (for review, James et al., 2018). We found that blocking Ox1Rs can 43 disrupt opioid seeking behaviors: systemic blockade of Ox1R signaling reduced breakpoints for 44 heroin in a progressive ratio task (Smith and Aston-Jones, 2012) and attenuated demand 45 (motivation) for remifentanil in a behavioral e...